Clinical aspects of hearing loss associated with cisplatin therapy – a review

Journal Title: Revista de Medicină Militară - Year 2014, Vol 0, Issue 3

Abstract

Introduction: Cisplatin is a well known platinum-based chemotherapeutic agent used for the treatment of diverse malignant tumours. A frequent side effect of cisplatin therapy is ototoxicity. Material and methods: Experimental, clinical studies and reviews from the English language medical literature concerning ototoxicity were selected either from PubMed or printed medical journals, pointing out cisplatin-induced ototoxicity. Molecular mechanisms, clinical audiological and histological marks of cisplatin-induced ototoxicity as well as current experimental and clinical strategies for prevention or treatment of hearing loss were reviewed. Results and discussion: A wide range of otoprotective molecules and efficient strategies against cisplatin-induced hearing loss proved to be helpful in experimental studies whereas only dexamethasone settled a slight otoprotective effect in a clinical study. Conclusion: There is no currently available treatment for cisplatin associated hearing loss and further research is required for future therapeutic options.

Authors and Affiliations

Felician Chirtes

Keywords

Related Articles

News and Perspectives on Treatment of Normal Pressure Internal Hydrocephalus

Many patients, usually over 60 years old, presenting presenile dementia associated with marked gait disorders, impaired balance, urinary incontinence, have been shown to have enlarged ventricles associated with relativel...

General considerations regarding the infections with the Escherichia coli pathogen

Escherichia coli is the species of the genus Escherichia with the greatest epidemiological impact. Escherichia coli infections are found mainly in places with poor hygiene; the infants with ages between 1 and 3 years old...

Download PDF file
  • EP ID EP196613
  • DOI -
  • Views 107
  • Downloads 0

How To Cite

Felician Chirtes (2014). Clinical aspects of hearing loss associated with cisplatin therapy – a review. Revista de Medicină Militară, 0(3), 19-29. https://europub.co.uk/articles/-A-196613